Salmon calcitonin (sCT) forms an amphipathic helix in the region 9-19, with the C-terminal decapeptide interacting with the helix (Amodeo, P., Motta, A., Strazzullo, G., and Castiglione Morelli, M. A. (1999) J. Biomolec. NMR 13, 161-174). To uncover the structural requirements for the hormone bioactivity, we investigated several sCT analogs. They were designed so as to alter the length of the central helix by removal and/or replacement of flanking residues, and by selectively mutating or deleting residues inside the helix. The helix content was assessed by circular dichroism and nuclear magnetic resonance (NMR) spectroscopies; the receptor binding affinity in human breast cancer cell line T 47D, and the in-vivo hypocalcemic activity were also evaluated. In particular, by NMR spectroscopy and molecular dynamics calculations, we studied [L 23 ,A 24 ]-sCT in which Pro 23 and Arg 24 were replaced by helix inducing residues. Compared with sCT, it assumes a longer amphipathic α-helix, with decreased binding affinity, and one-fifth of the hypocalcemic activity, therefore supporting the idea of a relationship between a definite helix length and bioactivity. From the analysis of other sCT mutants we inferred that the "correct" helix length is located in the 9-19 region and requires long-range interactions and the presence of specific regions of residues within the sequence for high binding affinity and hypocalcemic activity. Taken together, the structural and biological data identify welldefined structural parameters of the helix for sCT bioactivity.
defined structural parameters of the helix for sCT bioactivity.
The most recognized action of calcitonin (CT) 1 is the inhibition of osteoclast-mediated bone resorption. This forms the basis for its primary clinical use in the treatment of bonerelated disorders such as Paget disease, osteoporosis, and hypercalcemia of malignancy (1) . CT activity also includes modulation of renal ion excretion, analgesia, inhibition of appetite, and gastric acid secretion, as well as influence on reproduction via effects on embryological implantation and sperm function (1, and references therein). Recently, CT has been put forward as an ideal agent for treatment of osteoarthritis (2) .
CT is a single-chain polypeptide hormone of 32 amino acids with an N-terminal disulfide bridge between positions 1 and 7, and a Cterminal amidated proline. CT species so far studied can be subdivided into three major classes:
human/rodent, artiodactyl, and teleost/avian; of these, the members of the teleost/avian group are generally the most potent, although relative potency varies in a species-and isoform-specific manner (3) . The higher potency combined with a longer in-vivo half-life has led to fish-like CT, exemplified by salmon CT (sCT), as the standard form of CT used for the clinical treatment of bone disorders (4) . However, the usefulness of CT is limited by the development of clinical resistance. This can be due to development of circulating antibodies against non-human CT (5) , and/or loss of responsiveness Two questions arise: does the hormonereceptor interaction require a CT helix of definite length? Is the interaction simulated by any model amphipathic helix, as suggested by Kaiser? Since the higher affinity of sCT in binding CTRs involves residues within the C-terminus (amino acids [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] of the hormone (23) , that is, residues located outside of the helix (12), we designed an sCT mutant (referred to as [L 23 ,A 24 ]-sCT) in which Pro 23 and Arg 24 were substituted for Leu 23 and Ala 24 , respectively (24) . Insertion of two helix-promoting residues should prolong the helical C-terminus, so as to deal with the first question.
to CT, presumably via receptor down-regulation and inhibition of new receptor synthesis (6) . Furthermore, human CT (hCT) easily associates and precipitates as insoluble fibrils (7) , which limits its usefulness as a therapeutic.
Structure-activity relationship of CT from various species has been studied extensively. In organic solvents (8, 9) sCT assumes an amphipathic α-helix in the region [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] , while in sodium dodecyl sulfate (SDS) (10, 11 ) the helix spans the region 6-22, with the C-terminal tail folded back towards the helix. Molecular dynamics (MD) simulations (12) have indicated that the "stable" helix of sCT is confined in the region 9-19 with the flanking residues 6-8 and 20-22 acting as stabilizers, and the C-terminus interacting with the helix. Among the structural determinants suggested to explain CT bioactivity, a role for the central helix has been put forward for activity, aggregation and fibril formation. Kaiser and coworkers (13, 14) provided evidence that the model of an amphipathic helix in the region 8-22 is a useful guide to designing potent sCT activity, although the primacy of "conformational flexibility" over amphipathicity has been invoked as an important parameter for activity (15) . These apparently conflicting results could be explained by the existence of subtypes of CT receptor (CTR) showing variable affinity for helical and non-helical peptides (1, 16) . Alternative RNA splicing yields multiple CTR mRNA isoforms. In man, at least six potential variants exist (3, 17, 18) ; however, the most common human CTR isoforms differ by the presence (hCTRb) or absence (hCTRa) of a 16-amino acid insert between amino acids 174 and 175, within the first intracellular loop of the receptor (19) . Of these, the hCTRa is the major human receptor isoform and is expressed in essentially all tissues known to express the CTR. The α-helical central region of CT peptides has been reported to interact directly with the receptor NH 2 terminus (20) , and a short segment of the hCTRa, close to the transmembrane domain 1, is proximal to amino acid 19 of helix (21) . Furthermore, a strict relationship between the binding receptor affinity and the helicity of the hormone has been observed, with a correlation between amphipathicity and potency (16, 22) .
The second question was tackled by analyzing the conformational properties, by circular dichroism (CD) and nuclear magnetic resonance (NMR) spectroscopies, of a number of sCT analogs, showing variable helix length in SDS. Furthermore, we evaluated the receptor binding affinity and the in-vivo hypocalcemic activity, which were linked to the helical length and chemical properties of the hydrophobic face. Our structural and biological data, together with those of other CT analogs, suggest a strict relationship between the amphipathic α-helix of definite length, located in the 9-19 region, and the biological activity of sCT. Because of variability of calcitonin sequences in that region (in particular, for sCT and hCT 10 out of 16 of the amino acid substitutions are concentrated in the segment [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] , it is suggested that the helix does not have to be a "perfect" amphipathic α-helix, it can be distorted or somewhat shortened but located in the 9-19 region. Also important is the Leu distribution within the helix: in fact, CT bioactivity is altered when Leu is substituted for Ala, showing that the chemical properties of the hydrophobic side chains within the helix are relevant for receptor binding affinity and the invivo hypocalcemic activity. , were recorded at 600 MHz on a Bruker DRX-600 spectrometer, using an inverse multinuclear probehead fitted with gradients along the X-, Y-, and Z-axes. Spectra were referenced to internal sodium 3-(trimethylsilyl)-(2,2,3,3-2 H 4 ) propionate (Aldrich, Milwaukee, WI). Clean total correlation spectroscopy (TOCSY) (27, 28) and nuclear Overhauser enhancement spectroscopy (NOESY) (29) spectra were recorded by using the timeproportional phase incrementation of the first pulse, and incorporating the excitation sculpting sequence (30) for water suppression. We used a double-pulsed field gradient echo, with a soft square pulse of 4 ms at the water resonance frequency, with the gradient pulses of 1 ms each in duration. In general, 512 equally spaced evolution-time period t 1 values were acquired, averaging 16 transients of 2048 points, with 6024 Hz of spectral width. Time-domain data matrices were all zero-filled to 4K in both dimensions, thus yielding a digital resolution of 2.94 Hz/pt. Prior to Fourier transformation, a Lorentz-Gauss window with different parameters was applied for both t 1 αCH i -βCH i+3 (0.29 nm) cross-peaks. Finally, all of the distances calculated from NOESY spectra acquired with 0.10-s mixing time were used with a tolerance of +10%, while a 20% tolerance was allowed for those coming from spectra recorded at longer mixing time. The self-consistency of the choice of reference distances was checked in the resulting structures. Additional conformational restraints were inferred from 3 J NHα scalar couplings constraints. Only 11 scalar couplings were considered with values falling clearly below the 6-8 Hz region, a range which usually indicate rotationally averaged torsion angles (33) . Restraints on the trans amide bonds were also imposed. The ω dihedral angles were restrained in the range of 170-190 degrees. The β-methylene groups were stereospecifically assigned with the program HABAS (34) . A total of 15 (4, 5, 7, 9, 11, 12, 14-19, 22, 23, 26) out of 23 residues were stereospecifically assigned. When no stereospecific assignment was possible for methyl and methylene protons, the r -6 distance weighted ambiguous restraints were used.
EXPERIMENTAL PROCEDURES
The [L 23 ,A 24 ]-sCT starting structure was generated with the AMBER 6 package using the special residue database with reduced charges for amino acid side chains. We used the AMBER 91 all-atom forcefield (35) In all in-vacuo calculations a distance dependent dielectric function was used to mimic the presence of a high dielectric constant solvent, with a cutoff radius of 0.8 nm for nonbonded interactions and a residue-based pairlist routine. Structures were sampled and refined with a restrained simulated annealing (SA)/energy minimization (EM) approach previously described (36) giving a final set of 50 structures. Subsequently, MD calculations in methanol were performed on the lowest energy [L 23 ,A 24 ]-sCT structure using the particle mesh Ewald method (37) for calculating the full electrostatic energy of the unit cell. The AMBER-OPLS united atom force field (38) was employed for the peptide in conjunction with explicit methanol molecules and chloride counterions (39) . The [L 23 ,A 24 ]-sCT initial structure was first neutralized with 3 chloride ions and subsequently solvated with 3211 methanol molecules in a periodic rectangular box (edge lengths of 6.94, 4.81 and 5.07 nm). Preparation and equilibration of the unit cell prior to the 1000-ps production run was performed as reported (36) . Throughout the 1000-ps production run we collected coordinates, velocities and energy every 10 ps to perform statistical analysis. Simulations were performed in the nTP ensemble (T=300 K and P=1 atm) with a constant temperature and constant pressure relaxation times, respectively, of 0.05 and 0.2 ps for the equilibration runs, and 1 and 2 ps for the 1000-ps production run. The molecular graphics program MOLMOL (40) In-vivo hypocalcemic assay -Biological activity was estimated by in-vivo hypocalcemic activity assay. Eight week-old Wistar male rats (Japan SLC, Hamamatsu, Japan; Morini SAS, Polo D'Enza, Italy), whose body weights were in the range of 220-240 g, were used. Rats were withdrawn food at least 12 hr before experiments. All calcitonins were diluted with 1% gelatin in 0.9% NaCl solution at pH 3.2, and injected into subcutaneous space. Doses used were: 7.5, 25, 75, 250 and 750 ng/kg of body weight for sCT; and 25, 75, 250 and 750 ng/kg for different calcitonins. Blood (0.5 ml) was collected from the tail vein at 0, 1 and 3 hr after administration, and Ca 2+ level in plasma was measured by Ca 2+ /pH Analyzer (634, CIBA Corning Diagnostics).
Hypocalcemic response of each dose was normalized to that observed for 750 ng/kg of sCT, since it was found that a dose of 750 ng/kg of sCT was sufficient for the plateau to be reached. The following formula was used: The dose-response curve was made by linear regression, and 50% of effective dose (ED 50 ) value was calculated.
Cell culture -Human breast cancer T 47D cells were cultured as described (20) in RPMI 1640 containing 10% heat inactivated fetal bovine serum, 1% streptomycin/penicillin, 0.1 µM insulin, and 0.1 µM hydrocortisone in 5% CO 2 and 310 K. The latter hormones were omitted from the medium when subculturing cells to be used 1-3 days later for the receptor-binding assay. Subculturing was performed with trypsin/EDTA as described (41, 42) , and for the binding experiments cells were subcultured in 12-well dishes. Receptor binding experiments were performed when cells reached 90% confluence (1-3 days after subculture).
Receptor binding assay -The assay was performed according to established protocols (41) (42) . Briefly, cells in the 12-well dishes were washed with NaCl/P i (1 mL) at room temperature and then prewarmed (310 K) assay buffer (RPMI 1640 and 0.1% (w/v) bovine serum albumin) was added to the cells (950 µL). Lyophilized 125 Ilabelled sCT (5 µCi, specific activity 2000 µCi·mmol -1 ) was reconstituted in 100 mM HCl (200 µL), aliquoted at 277 K in eppendorf tubes (15 µL each), kept at 253 K and for each 12-well plate one tube was thawed at room temperature, diluted with assay buffer (250 µL) and used immediately. Twenty microliters of the 125 Ilabelled sCT solution (15.2 pmol) were then added to each well, and the wells were mixed by gentle shaking. Thereafter, solutions (50 µL) of different concentrations of the peptides in assay buffer were added to the cells, and following gentle mixing cells were incubated for 1 h at room temperature. Peptide solutions were freshly made prior to each experiment by diluting peptide stocks (≈ 500 µM in 1 mM HCl) (43) in assay buffer. Binding was terminated by aspiration of the medium and washing of the cells with NaCl/P i three times. Cells were then removed from the wells by short treatment (1 min) with 0.5 M NaOH (2 × 0.5 mL), and bound radioactivity was assessed by γ-counting (counter efficiency ≈ 75%). Nonspecific binding was determined as the binding of 100 nM sCT. This was assessed from 15 independent experiments to be 14.94% (± 3.36). Specific binding was the difference between total binding (tracer alone) and nonspecific binding.
CD Spectroscopy -Measurements were performed on a Jasco-J710 spectropolarimeter connected to a water bath used to control the temperature of the cell. Spectra were recorded in the far UV region (200-240 nm) at 300 K and pH 7.4 (20 mM phosphate, 100 mM NaCl) with a peptide concentration of 0.056 mM in a 1.0-cm path length cell. Spectra in the presence of 0.4 M SDS were acquired with a peptide concentration of 0.038 mM in a 0.1-cm path length cell. A spectral bandwidth of 2.0 nm and a scan speed of 10 nm/min were used. The precision of the data was improved by averaging five scans, and the results are reported as mean residue ellipticity (θ). Prediction of percentages of secondary structure from CD spectra was obtained using the k2d software, a Kohonen neural network with a two-dimensional output layer (44; www.emblheidelberg.de/~andrade/k2d).
RESULTS

Does the CT-receptor interaction require a helix of definite length?
Solution structure of [L 23 ,A 24 ]-sCT - Figure 1 shows the CD spectra of [L 23 ,A 24 ]-sCT at pH 7.4 and 300 K in water (broken line) and in SDS (continuous line). Estimation of the secondary structure with the k2d neural network algorithm (44) suggests the presence of 20% α-helix in water. In SDS, a dominant α-helix is clearly discernable, as two minima with high ellipticity values are observed at 220 and 208 nm, and we estimated the presence of 60% α-helix (mutant 19, Table 1 24 ]-sCT in methanol generated every 10 ps of the whole unrestrained MD, and the corresponding ribbon representation are reported in Figure 3A and 3B, respectively. 4 . This behavior has also been observed for sCT, while in hCT no ring residue is part of the helix. Residues in the region 4-9 are important for the stabilization of the amphipathic α-helix: in fact two long-range NOEs (NHLeu 4 -βLeu 9 , βLeu 4 -NHLeu 9 ), observed at all mixing times, suggest close interaction between the ring and the helix.
As previously described, methanol was the solvent of choice for simulations (12) . The α-helix ( Figure 3A) Figure 3B ). The disulfide bridge between Cys 7 (within the first turn of the helix) and Cys 1 (external to the helix) straddles the helix N-terminus, and it is associated with capping that stabilizes it. The NH groups of Thr 6 and Cys 7 , which cannot form intrahelical hydrogen bonds, are hydrogen bonded to the >C=O of Asn 3 sidechain, and to >C=O of Asn → N3/N4) and a hydrogen-bonded β turn between the >NH at N 3' and O=C< at Ncap. With regard to the C-terminus stabilization of the helix, a π αR -turn was identified. It is a generally occurring motif in α-helices as a distortion of the termini or in the middle (46) , and consists of an i+5 → i hydrogen bonded turn conformation (π turn), with the (i+4)th residue adopting an α R conformation. i+5 → i hydrogen bonds, as it is outlined in Figure 3B, 31 and Pro 32 , while the trans form was identified by the presence of an α i -δ i+1 NOE cross-peak. Usually, the relatively slow isomerization between cis and trans forms of prolyl peptide bond induces additional crosspeaks for nearby residues. In CT spectra, two Thr 31 cross-peaks were observed in the TOCSY fingerprint region. (adopting an α-helical conformation in the structures coming from SA/EM calculations) have all backbone dihedral angles near the observed mean values for α-helices (φ = -60 ± 15° and ψ = -40 ± 15°) with no RMS deviations greater than 12 degrees for any residue. Intrahelical NH(i) → CO(i-4) hydrogen bonds are also well conserved along the whole set of structures with percentages ranged from 87% to 99%. Both the N-terminus and the Cterminus patterns of helix-terminating hydrogen bonding remained essentially invariant, thus supporting the stability of the overall peptide folding. The time variation of φ and ψ dihedral angles along the 1000-ps unrestrained MD trajectory (not shown) confirms the stability of the [L 23 ,A 24 ]-sCT helix in the region 4-28. The only local correlated variations are observed for ψ29 and φ30, outside the helical region. The absence of any structural drift on the simulated time scale was also noted in a two-dimensional plot of the RMS deviation values (not shown), calculated from each pair of superimposed molecules, out of the 100 [L 23 ,A 24 ]-sCT conformations taken at regular intervals through the 1000-ps of the unrestrained MD simulations. We only observed local and reversible transitions. 23 ,A 24 ]-sCTCalcitonin exerts its biological activity upon binding a receptor that is a closely related member of the B family of G protein coupled receptors with putative seven transmembrane domain (for a review, see 1). Calcitonin receptors are widely distributed in the body but are most concentrated in the hypothalamus, bone, and kidney as well as in several cancer cell lines including the human breast-cancer cell line T 47D (42) . We have used the T 47D cell line to assess human receptor binding affinities of [L 23 ,A 24 ]-sCT as compared to sCT, the strongest known naturally occurring inhibitor, and hCT, a weak ligand. Binding affinities were evaluated via competitive inhibition of the specific binding of the radioligand 125 I-labelled sCT that binds with high affinity and selectivity to the calcitonin receptors of this cell line (47) . As shown in Figure 4, 
Receptor binding affinity of [L
Is the interaction simulated by any amphipathic helix? CD and NMR structural characterization of CT peptides in the absence and presence of SDS -
The CD spectra of CT, in the absence and in the presence of detergents, have been previously described by several authors. Table 1 reports the mean residue ellipticities observed for sCT and analogs, and hCT as reference, in the absence and in the presence of SDS.
Except for [A 12 ]-sCT (mutant 5), addition of SDS induces a helix in the central region of CT. We observed strong, non-ambiguous NH i -NH i+1 and medium αCHi-NH i+1 cross-peaks between all consecutive amino acids (as an example, see Figure 2 ): the presence of such sequential NOEs is a first indication of a helical structure, which is confirmed by the observation of several mediumrange NH i -NH i+2 , αCH i -NH i+3 , αCH i -NH i+4 and αCHi-βCH i+3 NOEs. We found that the helix percentage obtained by NMR was always higher than that estimated from CD spectra. , and hCT (peptide 23), the helix always covers the 9-19 region ( Figure 5 ). The percentage and the helix location for each mutant are reported in Table 1 .
In SDS-free solution, except for MCT-I and MCT-III (mutants 20 and 21), all reported calcitonins show no significant ordered structure. Prediction of secondary structure percentages from CD spectra with the k2d software (44) (Table  1) . On the contrary, hCT acquires much less helical structure than do sCT and mutants. Human CT is known to aggregate as a function of time (7); however, the concentrations used in our study are lower that those required for aggregation and no time or concentration dependence of the CD spectra were observed. Localization of the α-helix by NMR was delineated from the qualitative pattern recognition approach of the sequential and medium-range NOEs, as derived from 2D NMR experiments (33) . In water, at pH 7.4, we observed strong αCH i -NH i+1 connectivities along the whole peptide chain, and weak NH i -NH i+1 connectivities essentially concentrated in the central region. Furthermore, except for MCT-I (mutant 20), and MCT-III (mutant 21), we noticed scattered αCH i -NH i+2 and βCH i -NH i+1 connectivities, which argue for the presence of a structure fluctuating between an extended chain and a sequence of turns located in the central region of CT (33) . On the contrary, for MCT-I, and MCT-III, in the region Leu 8 -Leu 19 we observed weak αCH i -NH i+1 and strong NH i -NH i+1 connectivities, together with some medium-range NH i -NH i+2 , αCH i -NH i+3 , αCH i -NH i+4 and αCHi-βCH i+3 NOEs. They all hint at the presence of a well-defined α-helix also in water, with a percentage of 38 and 40% for MCT-I, and MCT-III, respectively (data not reported in Table 1 ).
In-vivo hypocalcemic activity and receptor binding affinity of CT mutants -We also studied the biological activity of CT mutants by investigating the in-vivo hypocalcemic activity and receptor-binding affinity, as described for [L 23 ,A 24 ]-sCT, and the results are reported in Table 2 . In order to assess the effect induced by the mutation introduced to synthesize the analogs, native sCT was also tested, and the 50% effective doses (ED 50 ) were calculated (see Experimental Procedures) from dose-response curves. Receptor binding affinity of CT mutants was estimated on the T 47D cell line, and compared with that of sCT and hCT (Table 2) . For each analog, the affinity was evaluated via competitive inhibition of the specific binding of the radioligand 125 I-labelled sCT to the calcitonin receptors of this cell line (47) , and was referred to the affinity of sCT (IC 50 (Table 2 ) and the helix (Table  1) , with an increase in the hypocalcemic activity. However, [A 9 ]-sCT (mutant 4) shows a dramatic reduction of the biological potency of sCT, suggesting that this residue is crucial for sCT receptor binding. In fact, deletion of Leu 9 in N α -Ac-sCT(8-32)-amide resulted in an 800-fold decrease in binding affinity (48 Table 2 ). In particular, the inactivity of sCT(1-23)-NH 2 (mutant 22) despite the helix, suggests that other factors must be considered. We therefore substituted Leu with Ala at the sites 9, 12, 16 and 19 (mutants 4-11) . Although the helix is preserved in all mutants (Table 1) Therefore, proper biological activity seems to require anchoring through Leu 9 and Leu 19 , and the presence of Leu 12 and Leu 16 for the proper receptor interaction. This is in line with the 20-fold increase of hCT hypocalcemic activity, obtained by replacing aromatic amino acids by Leu residues (24, 49) . The inactive sCT(1-23)-NH 2 (mutant 22) preserves all Leu residues at sites 9, 12, 16 and 19 but lacks the C-terminal region. It has been found for that CT in SDS takes up an amphipathic α-helix in the central region and an extended C-terminal tail (11, 12) . However, while in hCT the two structural elements are independent, in sCT the tail and the helix interact through the contacts His 17 17 . This would suggest that charged residues within the helix play a role in the helix-tail interaction (17) .
DISCUSSION
Although the molecular mechanism underlying CT bioactivity is not yet fully elucidated, it is well known today that the physiological effects of CT occur through receptor-mediated processes (1) . The sCT sequence has been reported to contain two separate domains: an "activation domain", that requires a minimum sequence of residues 3 to 6, and a "binding region" located between residues 9 to 32 (50) . Furthermore, the C-terminal CT sequence (between residues 12 and 32) binds to the N-extracellular terminal domain of the receptor, which had previously been suggested to be responsible for ligand binding (20) , while the N-terminal sequence (residues 1-11) interacts with the membrane embedded domain and the associated loops, which had been suggested before to be the signal transduction domain (20) . These results were confirmed by developing photolabile derivatives of sCT and hCT for photoaffinity labeling of CTR. It has been reported that the helical region [16] [17] [18] [19] In general, receptor binding, signal transduction, and in-vivo bioactivity of the calcitonins appear to be related to a variety of structural and conformational features that include the formation of an amphiphilic α-helix in the middle of the sequence (13, 14) , conformational flexibility (15) , long-range interactions of the helix with the N-terminal ring, as well as the Cterminus (11, 12) , the presence of specific regions and amino acid residues within the sequence, and also the aggregation propensity. A comparison between the structures of sCT and hCT (12) indicated that sCT has a longer central helix with the C-terminal tail folded toward the helix, while in the human form the helix is shorter and no interaction with the tail is present. Considering that sCT shows the highest bioactivity, while hCT the lowest, a prominent role can be inferred for the length of the central amphipathic helix and/or the folding back of the C-terminal region. We have investigated here several sCT mutants with variable helix length, and its effects on the hypocalcemic activity and receptor affinity. Furthermore, the analysis also confirmed a role for long-range interactions as well as strict requirements for the hydrophobic residues within the helix, and increased conformational flexibility. Mutants were selected to answer the following questions: does the interaction with the receptor require an sCT helix of definite length? Is the interaction simulated by any amphipathic helix? We firstly studied the solution conformation, the receptor binding affinity, and the hypocalcemic potency for [L 23 (12) . Significantly, no helix-tail interaction was observed for [L 23 ,A 24 ]-sCT. This is due to the conformational constraints imposed by the longer helix that reduces the hinge region required to allow the folding back of the C-terminus, as observed for sCT ( Figure 6 ). Therefore, the helix length and the folding back of the tail are strictly linked, giving sCT a wedge-shaped form that may be required for proper interaction with the receptor. (Table 2) but receptor-binding potency is identical or only slightly lower than sCT (Table 2 ). It is conceivable that mutations bring about local arrangements within the helix, which favor a better accommodation onto the receptor, in agreement with the increased conformational flexibility required for CT bioactivity (15 10) . Such a behavior might be linked to some unknown step in the receptormediated processes, and/or to mechanistic effect brought about by mutations. It is possible that "sliding" of the helix on the receptor surface locks the hormone in an active conformation similar, but not identical, to the native one. Although MCT-III preserves the amphipathic helix (19, 20) , it abrogates positively charged residues at sites 11 and 17, bearing Lys and His, respectively in native sCT, and inserts Lys 14 instead of Gln (see the primary structure in the footnote of Table 1 ). Furthermore, sCT(1-23)-NH 2 , which is fully helical (Table 1) , is completely inactive (Table 2) . Taken together, data on MCT-III and sCT(1-23)-NH 2 suggest that the native charge distribution with the helix-tail interaction, and the "right" helical length are sufficient to regulate sCT bioactivity. The data reported confirm the crucial role of the helix for CT bioactivity. However, the central region does not have to be postulated as a "perfect" amphipathic α-helix, and, indeed, the variability of the calcitonin sequences from different species also argues against such a conclusion. A "stable" α-helical region from residues 9-19, while exhibiting amphipathicity, is amenable to sequence variation, and at least some properties of the hormone "benefit" from imperfections in the segregation of hydrophobic and hydrophilic residues. Our results also indicated that an ideal amphipathic α-helix might not necessarily correlate with high CT bioactivity. Furthermore, the bioactivity is associated with specific local conformational features of the backbone, sidechains, and the shape of the molecule. It is conceivable that the more compact structure brought about by such conformational constraints also affects the rate of metabolic degradation and clearance, which is reduced by the presence of strong peptide secondary structure. Tables 1 and 2 . The region corresponding to the putative "biologically relevant helix" is shaded. Figure 6 . Superposition of the [L 23 ,A 24 ]-sCT mean structure (black) on the bundle of sCT solution structures (gray). Structures were superimposed for pairwise minimum RMS deviation of the N, Cα and C atoms of the common central helical region (residues 9-19). ---------------------------------------------------------------------------------------------------------------------------- 
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